GlassScriptPhysician profile
Melissa A Johnson
NPI 1528523867
$9,026.40
in general payments reported to CMS, 2019-2025
49 companies · $2,487 in 2025
The $2,487 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,463 · 2022: $2,598 · 2023: $910 · 2024: $567 · 2025: $2,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,964.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,061.51 | 2021-2025 | |
| Pfizer INC. | $790.64 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $683.72 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $612.70 | 2021-2025 | |
| Lilly USA, LLC | $573.55 | 2021-2025 | Kisunla, Amyvid |
| Janssen Pharmaceuticals, INC | $499.75 | 2021-2023 | Ponvory |
| Biogen, INC. | $466.35 | 2021-2025 | Vumerity, Spinraza, Tysabri |
| Biohaven Pharmaceutical Holding Company LTD. | $465.45 | 2022 | |
| Ucb, INC. | $444.83 | 2021-2025 | Briviact, Rystiggo |
| Biohaven Pharmaceuticals, INC. | $426.66 | 2021 | |
| Lundbeck LLC | $300.27 | 2021-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $276.38 | 2021-2025 | Ultomiris |
| Argenx US, INC. | $236.11 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $215.00 | 2021-2025 | Valtoco |
| Eisai INC. | $188.81 | 2022-2025 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $137.37 | 2021-2023 | Rytary |
| Astrazeneca Pharmaceuticals LP | $132.45 | 2021-2025 | Evusheld |
| Kyowa Kirin, INC. | $125.93 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $123.22 | 2021-2025 | Ingrezza |
| Scilex Pharmaceuticals INC. | $116.19 | 2021-2025 | |
| Sk Life Science, INC. | $105.64 | 2022-2024 | |
| W. L. Gore & Associates, INC. | $85.47 | 2022-2023 | Gore Cardioform Septal Occluder |
| Aquestive Therapeutics, INC. | $81.82 | 2021-2022 | |
| Genentech USA, INC. | $79.51 | 2023-2025 | Ocrevus Zunovo, Enspryng, Ocrevus |
| Currax Pharmaceuticals LLC | $77.39 | 2021-2025 | Onzetra Xsail, Contrave |
| Avanir Pharmaceuticals, INC. | $70.10 | 2021 | |
| Celgene Corporation | $58.73 | 2021-2023 | Zeposia |
| Stryker Corporation | $54.84 | 2023 | Stryker |
| Grifols USA, LLC | $51.30 | 2025 | Gamunex-C |
| Mallinckrodt Hospital Products INC. | $43.14 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $38.62 | 2022 | |
| Csl Behring | $36.05 | 2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $33.00 | 2023-2025 | Rexulti, Nuedexta |
| Merz Pharmaceuticals, LLC | $32.32 | 2021-2022 | |
| Corium, LLC | $31.99 | 2023 | Adlarity |
| Catalyst Pharmaceuticals, INC. | $30.90 | 2023-2025 | Fycompa |
| Cycle Pharmaceuticals INC | $27.63 | 2024-2025 | Tascenso Odt |
| Sunovion Pharmaceuticals INC. | $23.86 | 2022 | |
| Axsome Therapeutics, INC. | $23.46 | 2025 | Symbravo |
| Ge Healthcare | $20.30 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.26 | 2025 | |
| Medtronic, INC. | $17.78 | 2023 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $16.94 | 2024 | Hyqvia |
| Amgen INC. | $16.61 | 2022 | |
| Biotronik Nro, INC. | $16.38 | 2025 | Prospera |
| Otter Pharmaceuticals, LLC | $15.78 | 2025 | Sympazan |
| Life Molecular Imaging LTD | $15.71 | 2025 | Neuraceq |
| Avion Pharmaceuticals | $13.94 | 2023 | Dhivy |
| E.R. Squibb & Sons, L.L.C. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.